Status:
COMPLETED
Piloting 'mPal,' a Multilevel Strategy for Palliative Care Implementation
Lead Sponsor:
Laurie McLouth
Collaborating Sponsors:
National Center for Advancing Translational Sciences (NCATS)
Conditions:
Lung Cancer
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
The purpose of this study is to assess the feasibility and acceptability of mPal, a multilevel implementation strategy to improve palliative care use among advanced stage lung cancer patients receivin...
Detailed Description
In this study, 60 advanced stage lung cancer patients will be randomized to mPal's patient-level component or usual care. Oncology providers will receive the mPal intervention. mPal is designed to hel...
Eligibility Criteria
Inclusion
- new or recurrent AJCC stage IIIb-IV non-small cell lung cancer or extensive stage small cell lung cancer
- ECOG performance status 0-3/Karnofsky 40-100
- at least three weeks into active oncologic treatment (chemotherapy, immunotherapy, chemo-immunotherapy)
Exclusion
- unstable brain metastases
- Cognitive (i.e., dementia) or psychiatric condition (e.g., psychotic disorder) for which participating would be inappropriate
- Receiving palliative care
- Unable to speak and read English
Key Trial Info
Start Date :
July 28 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2024
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05270395
Start Date
July 28 2022
End Date
June 1 2024
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Kentucky
Lexington, Kentucky, United States, 40506